Abrus Precatorius Leaf Extract Reverses Alloxan/NicotinamideInduced Diabetes Mellitus in Rats Through Hormonal (Insulin, GLP-1, And Glucagon) And Enzymatic (α-Amylase/α- Glucosidase) Modulation Part 1
Mar 17, 2022
Please contact oscar.xiao@wecistanche.com for more information
Background
Abrus precatorius is used in folk medicine across Afro-Asian regions of the world. Earlier, glucose-lowering and pancreatic-protective effects of Abrus precatorius leaf extract (APLE) were confirmed experimentally in STZ/nicotinamide-induced diabetic rats; however, the underlying mechanism of antidiabetic effect and pancreatic protection remained unknown. Objective. This study elucidated antidiabetic mechanisms and pancreatic-protective effects of APLE in diabetic rats. Materials and Methods. APLE was prepared by the ethanol/Soxhlet extraction method. Total phenols and flavonoids were quantified calorimetrically after the initial phytochemical screening. Diabetes mellitus (DM) was established in adult Sprague-Dawley rats(weighing 120-180 g)of both sexes by daily sequential injection of nicotinamide(48 mg/kg; ip) and Alloxan (120mg/kg; ip)over a period of 7 days. Except for control rats which had fasting blood glucose (FBG) of 4.60 mmol/L, rats having stable FBG(16-21 mmol/L)7 days post-nicotinamide/Alloxan injection were considered diabetic and were randomly reassigned to one of the following groups (model, APLE(100, 200, and 400 mg/kg, respectively; PO) and metformin (300 mg/kg; PO)) and treated daily for 18 days. Bodyweight and FBG were measured every 72 hours for 18 days. On day 18, rats have sacrificed under deep anesthesia; organs (kidney, liver, pancreas, and spleen) were isolated and weighed. Blood was collected for estimation of serum insulin, glucagon, and (LP-1 using a rat-specitc ELSA kit,' The pancreas was processed. sectioned, and H&E-stained for histological examination. Effect of APLE on the enzymatic activity of alpha (a)-amylase and α-glucosidase was assessed. Antioxidant and free radical scavenging properties of APLE were assessed using standard methods. Results. APLE dose-dependently decreased the initial FBG by 68.67%,31.07%, and 4.39% compared to model(4.34%) and metformin (43.63%). APLE(100 mg/kg) treatment restored weight loss relative to the model. APLE increased serum insulin and GLP-1 but decreased serum glucagon relative to the model. APLE increased both the number and median cross-sectional area (×10°um') of pancreatic islets compared to that of the model. APLE produced a concentration-dependent inhibition of α-amylase and α-glucosidase relative to acarbose. APLE concentration-dependently scavenged DPPH and nitric oxide (NO)radicals and demonstrated increased ferric reducing antioxidant capacity (FRAC)relative to standards. Conclusion. The antidiabetic effect of APLE is mediated through modulation of insulin and GLP-1 inversely with glucagon, noncompetitive inhibition of c-amylase and α-glucosidase, free radical scavenging, and recovery of damaged/necro-apoptosis pancreatic β-cells.

Please click here to know more
1. Introduction
Diabetes mellitus(DM) is one of the metabolic syndromes characterized by chronic hyperglycemia culminating from dysregulated glucose metabolism secondary to defects in pan-creatic β-cell function [1]. Pathologically, DM is a product of errors in glucose metabolism due to defects in pancreatic β-cell function which occasions either insulin insufficiency(type 1 DM) or insulin resistance(type 2 DM).Common symptoms of DM include polyphagia,polydipsia,blurred vision, chronic loss in bodyweight,gastroparesis,and polyuria [2]. Over time, unresolved hyperglycemia increases the risk of microvascular complications of DM such as diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy [2]. These complications occur due to extensive oxidative stress and lipid peroxidation which are the byproducts of reactions between glucose and biological molecules [3]. Extensive glycosylation of biological molecules such as DNA, proteins, and lipids leads to the generation of unstable biochemical intermediates which serve as sources of reactive oxygen species (ROS) and nitrogen species(RNS).ROS and RNS are key drivers of oxidant and peroxidative reactions in various cells and tissues [3].
Epidemiologically, it is reported that DM affects over 387 million people worldwide [4]. This provisional estimate is projected to increase to 592 million by the year 2035 [5].Initially, DM was thought to be adult-onset, but now, DM is shown to be independent of age, which clearly shows the enormity of the threat posed by DM to global health.

Cistanche can improve immunity
Conventionally, treatment of DM(types 1 and 2)involves the use of antidiabetic agents, which are grouped as noninsulin (including the biguanides(e.g, metformin), sulfonylureas(e.g.,glyburide),SGLT-2 inhibitors(e.g, dapagliflozin), bile acid sequestrants (e.g., colesevelam), amylin mimetic(e.g, pramlintide),dopamine-2 agonist (e.g., bromocriptine), DPP-4 inhibitors (e.g, sitagliptin), GLP-1RAs (e.g, exenatide), thiazolidinedione (e.g, rosiglitazone), and α-glucosidase inhibitors (e.g., Acarbose and voglibose))and insulin (e.g., human insulin and analogs) therapies [6]. The conventional antidiabetic therapies have been proven effective despite the fact that the use of some of them is costive and may be associated with serious side effects[7]. Cost, side effects, and the general belief that conventional drugs are synthetic and for that matter unsafe compared to herbal medicines, which are thought to be"natural" and relatively safe have contributed to the renewed interest in the use of herbs and herb-derived products for the treatment and management of human diseases including DM[8,9]. This paradigm is quite common in poorer tropical countries of the world, where most people rely on herbal medicine to meet their primary health care needs [8]. Also, this may probably affirm the usual assertion that the use of herbs predates modern medicine and that natural products continue to serve as templates for the pharmaceutical synthesis of new drugs[10]including antidiabetic agents. Importantly, these herbs and herb-derived therapies are used as adjunctive therapy in a manner that reflects the belief systems and ethnobotanical heritage of most local communities across Afro-Asian regions of the world. For instance, many medicinal plants with ethnobotanical claims for the treatment of diabetes mellitus such as Chrysobalanus orbicularis[11], Spondias mombin and Mangifera indica[12], Sesamum indicum [13], and Bryophyllum pinnatum [14] have all demonstrated α-amylase and α-glucosidase inhibitory effects which are considered vital for glycemic control. It is in response to this renewed interest in the use of herbs and herb-derived products as an adjunctive or alternative therapy, that the World Health Organization(WHO)together with other interest groups has recommended incorporation of indigenous healing systems, particularly herbal medicine into healthcare systems of poorer countries [15]. This recommendation has necessitated the need to verify health claims on medicinal herbs commonly used by local people to treat human diseases[16,17]. Interestingly, Abrus pre-catorius commonly called "jequirity pea" is a medicinal herb extensively used in the folk medicine of many cultures across Afro-Asian regions of the world for the treatment of human diseases[18-20]. Several reports have highlighted the traditional uses of Abrus precatorius leaves in the treatment and management of diabetes mellitus[21-23]. Of note, extracts from leaves of Abrus precatorius have demonstrated efficacy against diabetes mellitus [1] and breast cancer [24], two human diseases that have contributed significantly to global disease burden [25]. Many studies have justified the ethnopharmacological uses and other medicinal claims of Abrus precatorius by demonstrating experimentally its biological properties including free radical scavenging [26], reno-protection [27], neuro-protection [28], immunomodulatory[19], anti-inflammatory [29],anti-lipotoxicity [30], and antiplatelet aggregation [31]just to mention but a sample.

Previously,glucose-lowering and pancreatic-protective effects of APLE were demonstrated experimentally in STZ/nicotinamide-induced diabetic rats to confirm its use as antidiabetic folk medicine by local people in the western region of Ghana [1]. However, the mechanism underlying the glucose-lowering and pancreatic-protective effects of APLE remained poorly elucidated. Presently, mechanisms underlying the glucose-lowering and pancreatic-protective effects of APLE such as modulation of insulin, glucagon, and GLP-1, inhibition of the enzymatic activity of α-amylase, and α-glucosidase, free radical scavenging, and recovery of pancreatic β-cell damage and necro-apoptosis were demonstrated in vivo and in vitro.
2. Materials and Methods
2.1. Drugs and Chemicals. Alloxan monohydrate(Sigma-Aldrich Co., St.Louis, MO, USA), nicotinamide(Sigma-Aldrich Co., St.Louis, MO, USA), acarbose (LGM Pharma, USA), metformin (Bristol laboratories Ltd.), gallic acid (Merck KGaA, USA), rutin(Acros organics, USA), ascorbic acid (Carl Roth, Germany), quercetin(Alfa Aesar, UK), p-nitrophenyl glucopyranoside (pNPG)(BBI Biotech, China), Rat Insulin ELISA kit, Rat Glucagon-ELISA kit, and Rat GLP-1 ELSA kit(Wuxi Donglin Sci & Tech Development Co.Ltd, China) were used in the study. All other solvents and chemicals used in the study were of analytical grade.
2.2. Collection, Identification, and Authentication of Abrus precatorius Leaves. Fresh leaves of A. precatorius were collected from uncultivated farmland at Sefwi Asawinso'A'(Bibiani-Ahwiaso-Bekwai District, Western Region, Ghana). The leaves were identified and authenticated by a qualified botanist at the herbarium unit, School of Biological Sciences, the University of Cape Coast, where a voucher specimen (CC3366) was deposited as previously reported [1].
2.3.Preparation of Abrus precatorius Leaf Extract(APLE). APLE was prepared according to a previous method [1]. Briefly, shade-dried leaves of A. precatorius were mechanically milled into fine powder. The powdered leaves were stored in airtight plastic containers prior to use. A 120g quantity of the powdered leaves was soaked in 700 mL of ethanol for 48 hours and covered with cheesecloth. The mixture was stirred at least 3 times per day. On the second day, the mixture was filtered through a filter paper fitted in a Buchner funnel. The filtrate was subjected to separation using a rotary evaporator mounted on a water bath. After retrieving ethanol using the rotary evaporator, the resultant dark-green syrupy liquid was dried in a desiccator for several weeks leaving a dark-green solid extract. The extract was labeled and stored in a desiccator prior to use. APLE was continuously prepared in order to obtain enough quantities for all experiments.
2.4.PhytochemicalScreening of APLE.APLE was screened for the presence of phytocompounds as previously reported [1]. 2.5.Determination of Total Phenolic Content (TPC) in APLE. Total phenolic content in APLE was determined by using the Folin Ciocalteu reagent method as previously described [32] with slight modifications. A dilute concentration of APLE (250μL of 1mg/mL)was mixed with 750μL Folin Ciocalteu reagent(1 in 10 dilutions with water) and 750μL of 7%Na, CO. The mixtures were then made up to 5mL with distilled water and incubated at room temperature for 2 hours for color development. Absorbance was then measured at 765 nm by using a spectrophotometer(UV-vis, T70 PG Instruments). After preparation of a standard gallic acid (0-300ug/mL)curve,TPC in APLE was extrapolated from the gallic acid calibration curve and expressed in gallic acid equivalent(GAE). All experiments were conducted in triplicates.
2.6.Determination of Total Flavonoid Content(TFC)in APLE. Total flavonoid content in APLE was measured per a previously described method [33] with a few modifications. Briefly,500μL of Abrus precatorius plant extract (1 mg/mL)prepared in 50% ethanol was mixed with 500 μL of 10% aluminium chloride(AlCl,.6H,O) and 1500μL of 10% sodium acetate(NAC,H,O,.3H,O). The reaction mixture was incubated at room temperature for 40 minutes, and absorbance was measured at 415 nm using a spectrophotometer(UV-vis, T70 PG Instruments). After preparation of the standard rutin (0-250ug/mL) calibration curve, TFC in APLE was extrapolated from the rutin calibration curve and expressed in rutin equivalent (RE). All experiments were carried out in triplicate.

2.7. Ethical Approval. All protocols involving animals were initially reviewed and approved by the Kwame Nkrumah University of Science and Technology (KNUST)Institutional Review Board on Animal Experimentation (FPPS/PCOL/006/2019). Also, experiments involving rats were carried out in accordance with the European Union Directives (2010/63/EU)on the use and care of animals in scientific experimentation. Animal suffering and the number of animals were reduced as much as possible in order to comply with the requirements in the 3R(Refinement, Replacement, and Reduction)recommendations [34].
2.8. Acquisition and Care of Experimental Animals. Healthy 7-8-week-old adult Sprague-Dawley rats of both sexes (weighing between 120 and 180g) were purchased from the Noguchi Medical Research Institute (NMRI), University of Ghana. Rats were later transported to the Animal House of the Department of Biomedical Sciences, University of Cape Coast, Cape Coast, Ghana. Rats were housed in stainless cages (34cm×47cm×18cm) with dry wood shavings as bedding, fed with normal rodent chow(GAFCO, TEMA), and had unrestricted access to water. Rats were maintained under ambient conditions of temperature, humidity, and normal dark/light cycle. However, these conditions were varied to suit the specific requirements of some experiments. Rats were allowed to habituate under these ambient and laboratory conditions for over two weeks before use in experiments.
2.9.Establishment of Alloxan/Nicotinamide-Induced Diabetes Mellitus in Rats. Experimental diabetes mellitus was established in overnight-fasted normoglycemic adult Sprague-Dawley rats according to a previously described method [1, 35] with some modification. Briefly, rats were sequentially injected with nicotinamide (48 mg/kg; IP) dissolved in normal saline solution and maintained on ice; then,15 minutes later, Alloxan (120mg/kg; ip) was reconstituted in 100 mM citrate buffer(pH4.5)solution was administered to rats daily for7 days. Subsequently,rats were given 5% glucose (5 mL/kg; PO)solution daily for 7 days.To confirm the establishment of hyperglycemia in rats, blood was collected from overnight-fasted rats 3-7 days post-Alloxan/nicotinamide and 5% glucose treatments using the tail-tip amputation method. Tails of rats were first wiped clean with sterile cotton dipped in 10% ethanol. Fasting blood glucose (FBG) was measured by using URIT G26 glucometer(URIT Medical Electronic Co., Ltd.).
2.10.Experimental Design. A curative rather than prophylactic treatment approach was adopted in this study, where after the establishment of experimental diabetes mellitus in rats, diabetic rats were subjected to various treatments. Figure 1 shows an outline of experiments carried out in this study. Rats having consistent FBG(11.1 mmol/L or >250mg/dL)upon multiple measurements were considered as having diabetes mellitus(hyperglycemia)[1,35].Confirmed diabetic rats were randomly assigned into five groups. Control rats were not exposed to Alloxan; instead, they were given normal saline. All groups were treated for a period of 18 days as shown below:

Control: normal saline(5 mL/rat/day;po)+rodent chow+water
Model: nicotinamide (48mg/kg ip)+ Alloxan(120mg/kg;ip)+ rodent chow + water
Metformin: nicotinamide (48mg/kg; ip)+ Alloxan (120 mg/kg; ip)+ metformin(300mg/kg; po)+ rodent chow + water
APLE(100 mg/kg): nicotinamide(48 mg/kg; ip)+Alloxan (120mg/kg; ip)+ APLE(100mg/kg; po)+ rodent chow+water
APLE(200 mg/kg): nicotinamide(48 mg/kg; ip)+ Alloxan (120mg/kg; ip)+ APLE(200mg/kg; po)+ rodent chow+water
APLE(400 mg/kg):nicotinamide(48 mg/kg; ip)+Aloxan (120mg/kg; ip)+ APLE(400mg/kg po)+ rodent chow+water
2.11. Measurement of Bodyweight. The body weight of rats was measured prior to the commencement of all animal experiments. Subsequently, the bodyweight of rats in all groups was measured every 3 days over 18 days. Doses were adjusted to reflect changes in body weight every 3 days. Finally, the body-weight of rats in all groups was measured prior to their sacrifice.
2.12. Blood Collection, Preparation of Sera, and Isolation of Organs. After weighing rats on day 18, rats were sacrificed under deep chloroform anesthesia. Blood samples were collected via cardiac puncture and then dispensed into labeled empty vacutainer tubes. Representative blood samples for each group were centrifuged at 3000rpm(Eppendorf centrifuge 5702,4°C)for 5 minutes. To obtain sera, the supernatant was collected into respectively labeled sample tubes. The liver, kidney spleen, and pancreas were harvested, freshly weighed, and fixed in 10% formalin.
2.13.Measurement of Serum Insulin, Glucagon, and GLP-1. Serum insulin, glucagon, and GLP-1 levels were, respectively, measured by using rat insulin ELISA(Wuxi Donglin Sci &Tech Development Co. Ltd, China), rat glucagon ELISA (Wuxi Donglin Sci & Tech Development Co.Ltd., China), and rat GLP-1 ELISA(Wuxi Donglin Sci & Tech Development Co.Ltd., China)strictly according to manufacturer's instructions.
2.14.Determination of Median Area of Pancreatic Islets of Langerhans. After histological processing of representative pancreas, resultant photomicrographs for respective groups were scanned by using Amscope MD35 eyepiece camera as previously described[1]. Each photomicrograph was uploaded onto Adobe photoshop CS6 and subsequently superimposed on a stereological grid. The number of intersections overlying the stroma of pancreatic islets was counted. Cross-sectional area of pancreatic islets of Langerhans of the representative pancreas was determined by using the Cavalieri method and point counting [36]. The cross sec-tional area was determined by the formula:

where
A represents cross-sectional area of pancreatic islets of Langerhans
XP represents the total number of intersections overlying the stroma of pancreatic islets
a/p represents the area per point of the stereological grid M represents the linear magnification.
2.15. Extraction of α-Amylase from the Pancreas of Guinea Pigs. After 20 hours of starvation, a guinea pig was sacrificed under deep anesthesia, and the pancreas was surgically removed. The pancreas was trimmed free of fat and any other tissue and immediately washed in sodium phosphate buffer (pH7.4). After weighing the pancreas, it was kept in a freezer at 4°C. The frozen pancreas was then homogenized(1g of the pancreas: 5 mL buffer) with ice-cold,0.1 M sodium phosphate buffer (pH of7.4)by using a homogenizer(WiseTis HG-15D homogenizer) and then centrifuged at 4400rpm for 30 minutes at 4°C. The supernatant was pipetted into separate microfuge tubes and stored in a freezer at-20°C. To confirm the extracted enzyme(α-amylase), a commercially available α-amylase was benchmarked with the extracted enzyme(α-amylase) using starch and iodine. Faint or disappearance of the blue-black coloration considered as an indication of α-amylase activity was compared to a control setup (no enzyme + starch + iodine) where there was a deep blue-black coloration.
2.16.Effect of APLE on α-Amylase Enzymatic Activity. Inhibition of alpha (α)-amylase enzymatic activity was assayed per a previous method [37] with some modifications. Briefly,APLE(125uL)or acarbose at increasing concentrations(100-1500 ug/mL) was added to a set of labeled test tubes containing 125 uL of α-amylase solution in 20mM sodium phosphate buffer (pH6.9). The APLE or acarbose/α-amylase mixture was preincubated at 25°C for 10 minutes. Subsequently,125 uL of 1% starch(prepared in 20mM phosphate buffer, pH=6.9)was added at selected time intervals. The reaction mixture in each case was incubated at 25°C for 10 minutes. Termination of each reaction was done at time intervals by adding 250uL of 3,5-dinitrosalicylic acid(DNSA) reagent and further heated in a water bath at 100℃C for 5 minutes, then allowed to cool to room temperature. Each reaction was made up to 2.5mL with distilled water and the absorbance was measured at 540 nm using a spectrophotometer(UV-vis, T70 PG Instruments). A control set-up was prepared using the same procedure except that α-amylase was preincubated with distilled water instead of APLE. Alpha(α)-Amylase inhibitory activity was calculated as follows:

2.17. Mode of Inhibition of α-Amylase Enzymatic Activity by APLE. The mode of inhibition of α-amylase enzymatic activity by APLE was done per a previous method [38] with some modification. Briefly,125 μL of APLE(5mg/mL) was first preincubated with 125 uL of α-amylase solution in 20mM phosphate at 25°Cfor 10 minutes in a set of labeled test tubes. Afterwards,125uL of starch solution at varying concentrations(0.3-5 mg/mL) was added to the reaction mixtures to
start the reaction. The reaction mixture was then incubated at 25℃ for 10 minutes before the addition of 250uL of 3,5-dinitrosalicylic acid (DNSA)reagent to stop the reaction. The amount of product formed was assayed by measuring the absorbance at a wavelength of 540nm using a spectrophotometer(UV-vis, T70 PG Instruments). The procedure was repeated for control set up by preincubation of α-amylase with a buffer instead of APLE. Lineweaver-Burk plot from the plot of Michaeles-Menten was done using Graph-Pad prism version 8(Graph Pad Software, San Diego, CA, USA)for the estimation of Km and Vmax. The mode of inhibition of α-amylase enzymatic activity by APLE was deduced from the estimated Km and Vmax.
2.18. Extraction of α-Glucosidase from the Small Intestines of Guinea Pigs. Extraction of α-glucosidase from the intestines of guinea pigs was performed according to a previous method [39] with some modifications. Briefly, guinea pigs were first starved for 20 hours and then sacrificed under deep anesthesia. The small intestine located immediately above the cecum and immediately below the duodenum was surgically removed and thoroughly rinsed in ice-cold 0.02 M sodium phosphate buffer(pH6.9)before dipping in fresh buffer solution. At a proportion of 1g of intestine-ne:5 mL of buffer, the isolated intestine was homogenized (WiseTis HG-15D homogenizer, Germany)at 4400rpm for 10 minutes at 2 minutes intermittent stoppages on ice. The homogenate was centrifuged (Eppendorf 5430R centrifuge)for 30 minutes at 4°C and the supernatant was gently harvested. Aliquots were put in 2mL cryotubes and kept at-20℃ for immediate use in experiments. To confirm the extracted enzyme(α-glucosidase), a commercially available α-glucosidase was benchmarked with the extracted enzyme(a-glucosidase) by incubating 50μL of 3mM p-nitrophenyl glucopyranoside(pNPG) with 25 μL of commercially avail-able α-glucosidase or 25 μL of the extracted enzyme (aα-glucosidase) at 25°C. Observation of a yellow p-nitrophenol product after 5minutes in each case was considered a confirmation of the activity of α-glucosidase.
2.19.Effect of APLE on α-Glucosidase Enzymatic Activity. The inhibitory effects of APLE and acarbose(a standard α-glucosidase inhibitor)were assessed per a previous method [40]with some modifications. Briefly, phosphate buffer (20mM;pH=6.9) was used to prepare p-nitrophenyl glucopyranose (pNPG)(substrate for α-glucosidase). In separate experiments, a-glucosidase(50 μL) was preincubated with increasing concentrations of APLE(25μL in each case), acarbose, or buffer for 10 minutes in each case. Afterward, 25uL of 3mM p-nitrophenyl glucopyranoside was added to either APLE/aα-glucosidase or acarbose/a-glucosidase preincubated mixture to start a reaction. The reaction mixture in each case was incubated at 25°℃ for 20 minutes. After 20 minutes of incubation, the reaction was stopped by adding 0.1 M Na,CO,(1 mL). A control was prepared using the same procedure except that α-glucosidase was preincubated with a buffer instead of APLE or acarbose. The reaction product (a yellow-colored p-nitrophenol) after the termination of the reaction was measured by using a spectrophotometer (UV-vis, T70 PG Instruments) at 405 nm for the determination of a-glucosidase activity. The results were expressed as a percentage of the control. In each case, experiments were repeated three times. Percentage(%)inhibition of α-glucosidase activity was estimated using the formula:

2.20. Mode of α-Glucosidase Inhibition by APLE. The mode of inhibition of α-glucosidase enzymatic activity by APLE was conducted according to a previous procedure [41] with some modifications. Briefly, in one set of test tubes, exactly 25 μL of 5 mg/mL of APLE was preincubated with α-glucosidase solution(50 μL) at 25°C for 10 minutes. In the second set of tubes, aα-glucosidase was preincubated with 50 μL of 20mM phosphate buffer(pH=6.9). Then,25uL of p-nitrophenyl glucopyranoside(PNP) at varying concentrations(0.3-3.0 mg/mL)was added to both sets of test tubes to start the reaction. The reaction mixtures were then incubated at 25°C for 20 minutes after which Na, CO, (1000μL) was added to terminate the reaction. The amount of product released was measured spectrophotometrically using a p-nitrophenol standard curve and converted to reaction velocities, (v). A double reciprocal plot(1/v against 1/S)where S is substrate concentration was plotted. The mode of inhibition of α-glucosidase activity by APLE was determined by analysis of the Line weaver-Burk plot.
2.21. Assessment of 2,2-Diphenyl-1-Picrylhydrazy(DPPH)Radical Scavenging Activity. DPPH radical scavenging activity was carried out according to a previous method [42] with some modification. Briefly, a 2mL reaction mixture was prepared by mixing DPPH(1.0 mL of 0.135mM)prepared in methanol and 1.0mL of varying concentrations of APLE (40,80,120,160,and 200 ug/mL) or ascorbic acid. The reaction mixture was shaken vigorously and left in the dark at room temperature for 30 minutes. The absorbance was measured(UV-vis, T70 PG Instruments) at 517nm against a blank. All tests were performed in triplicates. An equal amount of methanol and DPPH solution served as control. DPPH radical scavenging activity was estimated by using the formula:

2.22.Nitric Oxide (NO) Radical Scavenging Assay. NO radical scavenging activity of APLE and standards were estimated using Griess Illosvory reaction as previously described [43]with some few modifications. Briefly, the Griess Ilosvory reagent utilized 0.1%(w/v) naphthyl ethylene diamine dihydrochloride instead of 5% 1-naphthyl amine. Varying concentrations
(0-800ug/mL)of both APLE and standards(gallic acid and ascorbic acid) prepared and made up to 167uL were placed in labeled test tubes, and then,667 uL of 10mM sodium nitroprusside was added. Sodium phosphate buffer(167uL, pH7.4)was then added, and the mixture was incubated at 25°℃ for 150 minutes. Afterward, a 2000 μL sulfanilic acid reagent(0.33% in 20% glacial acetic acid) was added and allowed to stand for 5 minutes for the completion of the reaction of diazotization. Finally, a further 2000μL of 0.1%napthyl ethylene diamine dihydrochloride was added, mixed, and was then allowed to stand for 30 minutes at 25°C. The nitrite concentration was measured (UV-vis, T70 PG Instruments) at 546nm and was calculated with the control nitrate solution which had no APPLE/or standards but had all other components of the reaction mixture. Sodium phosphate buffer was used as a blank solution. Percentage(%)NO scavenging ability of APLE and standards was calculated using the formula:

where Ac is the absorbance of the control and At is the absorbance of the test (APLE/standard).
2.23.Ferric Reducing Antioxidant Capacity(FRAC) Assay. FRACwas assayed per the previous method [44] with few modifications. Briefly, the reaction comprised 250uL APLE/standard solution at different concentration(12.5-200ug/mL), 625 uL of sodium phosphate buffer(0.2M at pH6.6), and 625 uL of 1% potassium ferric cyanide, [K,Fe(CN)] into various test tubes. These were incubated for 20 minutes at 50°℃ to complete the reaction. Then, 625uL of 10% trichloro acetic acid (TCA)solution was added to the test tubes. The total mixture was centrifuged at 3000rpm for 10 minutes, after which 1800 uL supernatant was taken and mixed with 1800 μL of distilled water. Afterward,360 μL of 0.1% ferric chloride(FeCl,)solution was added and thoroughly mixed. The absorbance of the solution was measured at 700nm using a spectrophotometer(UV-vis, T70 PG Instruments) against the reaction blank. A typical blank solution containing the same solution mixture without APLE/or quercetin was incubated under similar conditions. Increased absorbance of the reaction mixture indicates increased reducing capacity. The experiment was repeated three times at each concentration. FRAC was measured as quercetin equivalent (QE).
2.24. Estimation of ICs and ECs0 To determine IC and ECsoof APLE with respective to its antioxidant, free radical scavenging, and inhibitory effect on α-amylase and α-glucosidase enzymatic activity, a series of increasing concentrations of APLE was tested against the respective activities. After converting the concentrations to logout was plotted on the horizontal axis against the % maximal activities(antioxidant, free radical scavenging, and inhibitory effect on α-amylase and a-glucosidase enzymatic activity)on the vertical axis. The concentration of APLE that produced 50% of the maximal activities (antioxidant,

free radical scavenging, and inhibitory effect on α-amylase and a-glucosidase enzymatic activity) assayed was determined graphically using GraphPad prism version 8 statistical software.
2.25. Statistical Analysis. Data obtained were presented as mean±SD. Statistical analysis was done by using Graph Pad Prism Version 8 for Windows(Graph Pad Software, San Diego, CA, USA). Mean comparison between groups was done by using one-way analysis of variance(ANOVA)followed by Tukey's multiple comparison tests. P≤0.05 was considered statistically significant in all analyses.
This article is extracted from Hindawi BioMed Research International Volume 2021, Article ID 9920826, 17 pages https://doi.org/10.1155/2021/9920826






